Podcasts about eyepoint pharmaceuticals

Dr. Jay Duker joins the program to discuss his transition from chair of an ophthalmology department to President & CEO of Eyepoint Pharmaceuticals.Disclosures: Dr. Duker is President & CEO of Eyepoint Pharmaceuticals. Dr. Sridhar has consulted for Eyepoint Pharmaceuticals.You can claim CME credits for prior episodes via the AAO website. Visit https://www.aao.org/browse-multimedia?filter=Audi

In this “golden age” of biotech, why is it so hard for so many companies to raise money? According to Nancy Lurker, former CEO of EyePoint Pharmaceuticals, it comes down to a shortfall in communications skills. Listen to Nancy's practical advice for entrepreneurs, and hear why she remains optimistic about the future of healthcare innovation.

On today's program, Boston Business Journal reporter Greg Ryan talks about efforts to alleviate the housing shortage in Boston. The CEO of EyePoint  Pharmaceuticals,Jay Duker, joins us to discuss his decision to stay in Massachusetts. Scott Kirsner, Innovation Reporter  for The Boston Globe, talks about items that are still made in Massachusetts. Skip Perham, Suffolk University Professor of Sports business, explains the upcoming sale of the Boston Celtics. And finally, Rob Whitten, founder of Ping, explains how his new drive-through coffee machine works.

This content has been developed for healthcare professionals only. Patients who seek health information should consult with their physician or relevant patient advocacy groups.For the full presentation, downloadable Practice Aids, slides, and complete CME information, and to apply for credit, please visit us at PeerView.com/FHQ865. CME credit will be available until December 15, 2024.Retinal Disease in the ED: “See Me Now”- A Primer for Emergency Physicians on the Recognition and Differential Diagnosis of Retinal Vein OcclusionsThis activity has been planned and implemented in accordance with the accreditation requirements and policies of the Accreditation Council for Continuing Medical Education (ACCME) through the joint providership of the American College of Emergency Physicians and PVI, PeerView Institute for Medical Education. The American College of Emergency Physicians is accredited by the ACCME to provide continuing medical education for physicians.This activity is developed in collaboration with our educational partner, PVI, PeerView Institute for Medical Education.SupportThis activity is supported by an independent medical education grant from Regeneron Pharmaceuticals, Inc.DisclosuresRobert M. Hughes, DO, has no financial interests/relationships or affiliations in relation to this activity.Christina Y. Weng, MD, MBA, has a financial interest/relationship or affiliation in the form of:Consultant and/or Advisor for Alcon; Allergan/AbbVie Inc.; Alimera Sciences; Apellis Pharmaceuticals; Dutch Ophthalmic Research Center (DORC); EyePoint Pharmaceuticals, Inc.; Genentech, Inc.; IVERIC bio, Inc.; Novartis Pharmaceuticals Corporation; Regeneron Pharmaceuticals Inc.; and REGENXBIO.Grant/Research Support from AGTC; Alimera Sciences; and DRCR Retina Network.Other Financial or Material Support in the form of royalties from Springer Publishers.Medical DirectorKristin Tomlinson, PhD, has no financial interests/relationships or affiliations in relation to this activity.

This content has been developed for healthcare professionals only. Patients who seek health information should consult with their physician or relevant patient advocacy groups.For the full presentation, downloadable Practice Aids, slides, and complete CME information, and to apply for credit, please visit us at PeerView.com/FHQ865. CME credit will be available until December 15, 2024.Retinal Disease in the ED: “See Me Now”- A Primer for Emergency Physicians on the Recognition and Differential Diagnosis of Retinal Vein OcclusionsThis activity has been planned and implemented in accordance with the accreditation requirements and policies of the Accreditation Council for Continuing Medical Education (ACCME) through the joint providership of the American College of Emergency Physicians and PVI, PeerView Institute for Medical Education. The American College of Emergency Physicians is accredited by the ACCME to provide continuing medical education for physicians.This activity is developed in collaboration with our educational partner, PVI, PeerView Institute for Medical Education.SupportThis activity is supported by an independent medical education grant from Regeneron Pharmaceuticals, Inc.DisclosuresRobert M. Hughes, DO, has no financial interests/relationships or affiliations in relation to this activity.Christina Y. Weng, MD, MBA, has a financial interest/relationship or affiliation in the form of:Consultant and/or Advisor for Alcon; Allergan/AbbVie Inc.; Alimera Sciences; Apellis Pharmaceuticals; Dutch Ophthalmic Research Center (DORC); EyePoint Pharmaceuticals, Inc.; Genentech, Inc.; IVERIC bio, Inc.; Novartis Pharmaceuticals Corporation; Regeneron Pharmaceuticals Inc.; and REGENXBIO.Grant/Research Support from AGTC; Alimera Sciences; and DRCR Retina Network.Other Financial or Material Support in the form of royalties from Springer Publishers.Medical DirectorKristin Tomlinson, PhD, has no financial interests/relationships or affiliations in relation to this activity.

Karen Zaderej is Chairman, Chief Executive Officer, and President of Axogen Corporation ( https://www.axogeninc.com/ ), a leading company focused specifically on the science, development and commercialization of technologies for peripheral nerve regeneration and repair, with a primary goal of restoring peripheral nerve function and quality of life to patients with physical damage or discontinuity, providing innovative, clinically proven and economically effective repair solutions for surgeons and health care providers. Karen joined the company in May 2006 and has served as President, Chief Executive Officer and a Member of the Board of Directors since September 2011 and became Chairman of the Board of Directors in May 2018, and has previously held positions as Chief Operating Officer and as Vice President of Marketing and Sales. Previous to joining the company, Karen founded Zaderej Medical Consulting, which assisted medical device companies build and execute successful commercialization plans. From 1987 to 2004, Karen worked at Ethicon, Inc., a Johnson & Johnson company, where she held senior positions in marketing, business development, research & development, and manufacturing. Karen is a member of the University of Tampa Board of Trustees and sits on the Board of Directors for EyePoint Pharmaceuticals, Inc. Karen has an MBA from the Kellogg Graduate School of Business and a BS in Chemical Engineering from Purdue University. Support the show

Nancy Lurker, CEO and Board Director of EyePoint Pharmaceuticals, aims to prevent the progression of blindness by developing technology that addresses retinal eye diseases. These back of the eye diseases are age-related and an increasing threat to populations worldwide. Current treatments require regular injections in the eye. The micro inserts developed by EyePoint will allow the drug to work for six months, allowing patients more flexibility to maintain their vision.  Nancy explains, "We know that if you look at the current eye treatments on the market today, wet AMD, retinal vein occlusion, diabetic macular edema, and diabetic retinopathy, all of those are running close to $30 to $40 billion being spent to help to treat these terrible eye diseases which may lead to blindness." "So, what causes these diseases? There's a genetic component at times, but also age plays a factor. And then, of course, diabetic macular edema and diabetic retinopathy can be caused for patients who have diabetes. So. what happens is you get a proliferation of tiny, tiny micro capillaries in the eye and, in some cases, just general atrophy of these retinal epithelia. These cells help to allow you to see. And what happens is when you start to get this proliferative growth that goes on and leakage of fluid and cells into the back of the eye, it completely obstructs your vision, which grows over time." "The vast majority of patients have to get another injection every month or every other month to slow the progression or stop it. And if you miss a visit, that fluid will come right back, and remember, the fluid is very, very bad for the eye. And we can see in the large databases, it's the medical claims data from patients, millions of these patients, we can see that even though they go in and get their eyes injected, you miss visits. Why? Life happens." @EyePointPharma #EyePointPharma #Ophthalmology #RetinalEyeDiseases #WetAMD #RetinalVeinOcclusion #DiabeticMacularEdema #DiabeticRetinopathy eyepointpharma.com Listen to the podcast here

Nancy Lurker, CEO and Board Director of EyePoint Pharmaceuticals, aims to prevent the progression of blindness by developing technology that addresses retinal eye diseases. These back of the eye diseases are age-related and an increasing threat to populations worldwide. Current treatments require regular injections in the eye. The micro inserts developed by EyePoint will allow the drug to work for six months, allowing patients more flexibility to maintain their vision.  Nancy explains, "We know that if you look at the current eye treatments on the market today, wet AMD, retinal vein occlusion, diabetic macular edema, and diabetic retinopathy, all of those are running close to $30 to $40 billion being spent to help to treat these terrible eye diseases which may lead to blindness." "So, what causes these diseases? There's a genetic component at times, but also age plays a factor. And then, of course, diabetic macular edema and diabetic retinopathy can be caused for patients who have diabetes. So. what happens is you get a proliferation of tiny, tiny micro capillaries in the eye and, in some cases, just general atrophy of these retinal epithelia. These cells help to allow you to see. And what happens is when you start to get this proliferative growth that goes on and leakage of fluid and cells into the back of the eye, it completely obstructs your vision, which grows over time." "The vast majority of patients have to get another injection every month or every other month to slow the progression or stop it. And if you miss a visit, that fluid will come right back, and remember, the fluid is very, very bad for the eye. And we can see in the large databases, it's the medical claims data from patients, millions of these patients, we can see that even though they go in and get their eyes injected, you miss visits. Why? Life happens." @EyePointPharma #EyePointPharma #Ophthalmology #RetinalEyeDiseases #WetAMD #RetinalVeinOcclusion #DiabeticMacularEdema #DiabeticRetinopathy eyepointpharma.com Download the transcript here

In this episode, Veeral Sheth, MD, sits down with Jay Duker, MD, the president and chief operating officer of Eyepoint Pharmaceuticals, for a discussion on his storied career in ophthalmology, the importance of fostering a relationship between clinicians and industry, and the current biotech Dr. Duker and team are working on at Eyepoint.  Please direct any podcast-related inquiries to ciapoce@mjhlifesciences.com. 

As the tidal wave of Gen Z hits the workforce, what do leaders need to know? Nancy Lurker, CEO of EyePoint Pharmaceuticals, has a reliable source -- her own daughter. The answers may surprise you.

In this episode, I chat with Nancy Lurker, CEO and board director, about EyePoint Pharmaceuticals and their latest treatments and trials. Brought to you by Alcon ·       Welcome to another exciting episode of Eye Care insider :13 ·       Intro Nancy Lurker :22 ·       Lurker's background :58 ·       EyePoint Pharmaceuticals: the origin and transition 2:29 ·       Yutiq and long-acting drug delivery systems 6:07 ·       Additional indications for Yutiq 8:30 ·       What is the key factor in delivering this longer durability? 16:13 ·       Any consideration of looking at superiority of visual acuity and anatomical OCT gains? 21:47 ·       Is the primary focus wet AMD? Or are you also looking at NPDR and DME as potential indications? 24:19 ·       Investor information and neural protection data 29:01 ·       What is the most important issue that the field of ophthalmology is currently facing? 30:38 ·       Thanks for listening 32:37 We'd love to hear from you! Send your comments/questions to Dr. Mali at eyecareinsider@healio.com. Follow us on Twitter @Healio_OSN. You can find Nancy Lurker at @EyePointCEO and @EyePointPharma. Nancy Lurker is the board director and CEO of EyePoint Pharmaceuticals. Disclosures: Lurker is the board director and CEO of EyePoint Pharmaceuticals. Mali reports he is founder and CEO of Mali Enterprises; retina medical director at Macular Degeneration Association; consultant/speaker for Genentech and Roche; equity owner for SNAPS; and grant/consultant for RetinAI.

In this episode, I share my thoughts about the five greatest innovations of the 21st century in the field of ophthalmology and how they have changed patient outcomes for the better. Brought to you by Alcon Welcome to another exciting episode of Eye Care insider :50 My review of the top five innovations in ophthalmology 1:02 Greatest Innovation #1 – anti-VEGF medications 2:06 Greatest Innovation #2 – intraocular lens implantation technology 3:26 Greatest Innovation #3 – electronic medical records 4:08 Greatest Innovation #4 – optical coherence tomography 5:48 Greatest Innovation #5 – telemedicine 6:35 Thanks for listening 7:44 We'd love to hear from you! Send your comments/questions to Dr. Mali at eyecareinsider@healio.com. Follow us on Twitter @Healio_OSN. Disclosures: Mali reports he is founder and CEO of Mali Enterprises; retina medical director at Macular Degeneration Association; grant/research support from Alimera Sciences, Allergan/AbbVie, Chengdu Kanghong Biotechnology, Genentech, Notal Vision, Regeneron and Santen; consulting for Alimera Sciences, Allergan/AbbVie, Eyepoint Pharmaceuticals, Genentech, Kala Pharmaceuticals, Macular  Degeneration Association, Notal Vision, Novartis, Regeneron and Sun Pharmaceuticals; speaker bureau for Alimera Sciences, Genentech, Kala Pharmaceuticals, Macular Degeneration Association, Notal Vision, Novartis and Sun Pharmaceuticals; and stock/shareholder with AbbVie and Regeneron.

In this episode, I share my review of the hot topics from the AAO 2022 annual meeting and share my thoughts on the new data shared about drug trials and treatments. Brought to you by Alcon Welcome to another exciting episode of Eye Care insider :53 My review of the hot topics from the AAO 2022 annual meeting 2:20 Hot Topic #1 – wet AMD treatments 2:40 Hot Topic #2 – high-dose Eylea 6:20 Hot Topic #3 – geographic atrophy treatments 10:24 Thanks for listening 16:04 We'd love to hear from you! Send your comments/questions to Dr. Mali at eyecareinsider@healio.com. Follow us on Twitter @Healio_OSN. Disclosures: Mali reports he is founder and CEO of Mali Enterprises; retina medical director at Macular Degeneration Association; grant/research support from Alimera Sciences, Allergan/AbbVie, Chengdu Kanghong Biotechnology, Genentech, Notal Vision, Regeneron and Santen; consulting for Alimera Sciences, Allergan/AbbVie, Eyepoint Pharmaceuticals, Genentech, Kala Pharmaceuticals, Macular Degeneration Association, Notal Vision, Novartis, Regeneron and Sun Pharmaceuticals; speaker bureau for Alimera Sciences, Genentech, Kala Pharmaceuticals, Macular Degeneration Association, Notal Vision, Novartis and Sun Pharmaceuticals; and stock/shareholder with AbbVie and Regeneron.

In this episode, I share my preview of the hot topics for the upcoming AAO 2022 annual meeting, including my thoughts on ocular gene therapy and new treatments in the works. Welcome to another exciting episode of Eye Care insider :52 My preview of hot topics for the upcoming AAO 2022 annual meeting 1:04 Hot Topic #1 – new treatments for dry AMD or geographic atrophy 2:43 Hot Topic #2 – wet AMD management 5:55 Hot Topic #3 – ocular gene therapy 7:56 Hot Topic #4 – biosimilars 9:17 Thanks for listening 11:22 We'd love to hear from you! Send your comments/questions to Dr. Mali at eyecareinsider@healio.com. Follow us on Twitter @Healio_OSN. Disclosures: Mali reports he is founder and CEO of Mali Enterprises; retina medical director at Macular Degeneration Association; grant/research support from Alimera Sciences, Allergan/AbbVie, Chengdu Kanghong Biotechnology, Genentech, Notal Vision, Regeneron and Santen; consulting for Alimera Sciences, Allergan/AbbVie, Eyepoint Pharmaceuticals, Genentech, Kala Pharmaceuticals, Macular Degeneration Association, Notal Vision, Novartis, Regeneron and Sun Pharmaceuticals; speaker bureau for Alimera Sciences, Genentech, Kala Pharmaceuticals, Macular Degeneration Association, Notal Vision, Novartis and Sun Pharmaceuticals; and stock/shareholder with AbbVie and Regeneron.

In this episode, Jose O. Segura, wealth management advisor and certified business exit planner, discusses establishing objectives within financial planning and organization, how to diversify your portfolio in ever-changing markets and more. Intro :38 Welcome to another episode of Eye Care insider :52 About Jose Segura 1:03 For people that are listening for the first time, do you mind giving a brief of your background? 1:32 What are, in your opinion, some best practices in regard to financial planning? 2:58 Process for financial organization and seeking out advisors. 10:09 Can you talk about the importance of portfolio diversification? 12:07 Importance of maintaining your overall focus on financial planning and strategies when markets are effected. 16:56 Could you give us one pearl for our listeners, or one key economic update that you think would be really important to the current economic situation right now? 18:49 Thank you Jose 23:09 Any final words to our listeners? 23:11 Outro 23:35   Jose O. Segura, is a wealth management advisor and certified business exit planner. We'd love to hear from you! Send your comments/questions to Dr. Mali at eyecareinsider@healio.com. Follow us on Twitter @Healio_OSN. For more information about Segura, visit www.joseosegura.com, reach him by email at jose_segura@wagllc.com, or call 518-867-3210 x104. Disclosures: Mali reports he is founder and CEO of Mali Enterprises; retina medical director at Macular Degeneration Association; grant/research support from Alimera Sciences, Allergan/AbbVie, Chengdu Kanghong Biotechnology, Genentech, Notal Vision, Regeneron and Santen; consulting for Alimera Sciences, Allergan/AbbVie, Eyepoint Pharmaceuticals, Genentech, Kala Pharmaceuticals, Macular Degeneration Association, Notal Vision, Novartis, Regeneron and Sun Pharmaceuticals; speaker bureau for Alimera Sciences, Genentech, Kala Pharmaceuticals, Macular Degeneration Association, Notal Vision, Novartis and Sun Pharmaceuticals; and stock/shareholder with AbbVie and Regeneron. Segura reports he is a registered Representative and Financial Advisor of Park Avenue Securities LLC (PAS), 355 Lexington Avenue, 9 Fl., New York, NY 10017, 212-541-8800.

In this episode, Ashlie Leal, director of ophthalmology at FundamentalVR, discusses their fully immersive surgical training products, how virtual reality plays a role in training surgeons and more. Intro :38 Welcome to another episode of Eye Care insider :52 About Ashlie Leal 1:00 Give me a little bit of your background – how you got into this industry and your role at FundamentalVR? 1:33 Can you give our listeners some background about FundamentalVR as a company, and why should eye care professionals start paying attention to your company? 2:56 Do you target training programs? … Is there a certain focus to your company in regards to demographics? 4:12 Is there any way you can describe [your virtual reality products] or any current product offers that you have that apply to eye care professionals? 7:30 You're using a headset and the two arms. Is that all you would need, or would you need some sort of base mannequin head with an eyeball simulation? 9:25 You can do it anywhere, theoretically? And you can simulate different MIGS equipment and different ocular lens implants based on the tech simulating that equipment? 10:59 So, the simulation is able to carry out these multiple, intricate steps? 12:03 Is there current gene therapy that is utilizing your technology? Do you have a relationship with them in the sense that you provide the surgeons with the virtual reality simulations? 12:49 Do you have any sort of data or any procedure done with virtual reality improving complication rate and efficiency? 14:02 What does the future look like for virtual reality? What would you say is the major challenge, or what does your company hope to accomplish in the next few years or the decade? 15:30 What's that process look like for a company to approach you for virtual reality offering to train on a new device? How long does that process take, and what are the steps to assimilate their product into your technology? 17:14 If someone wants to learn more, how can they contact you or your company for more information? 19:13 Congratulations Ashlie and FundamentalVR 19:39 Any final words to our listeners? 20:02 Outro 20:39   Ashlie Leal is director of ophthalmology, FundamentalVR. We'd love to hear from you! Send your comments/questions to Dr. Mali at eyecareinsider@healio.com. Follow us on Twitter @Healio_OSN. Leal can be reached on LinkedIn or at www.fundamentalsurgery.com.    Disclosures: Mali reports he is founder and CEO of Mali Enterprises; retina medical director at Macular Degeneration Association; grant/research support from Alimera Sciences, Allergan/AbbVie, Chengdu Kanghong Biotechnology, Genentech, Notal Vision, Regeneron and Santen; consulting for Alimera Sciences, Allergan/AbbVie, Eyepoint Pharmaceuticals, Genentech, Kala Pharmaceuticals, Macular Degeneration Association, Notal Vision, Novartis, Regeneron and Sun Pharmaceuticals; speaker bureau for Alimera Sciences, Genentech, Kala Pharmaceuticals, Macular Degeneration Association, Notal Vision, Novartis and Sun Pharmaceuticals; and stock/shareholder with AbbVie and Regeneron. Leal reports she is director of ophthalmology at FundamentalVR.

In this episode, Allisa Song, a medical student and the CEO and co-founder of Nanodropper, discusses the inception of the device, how it can benefit the eye care industry and more. Intro :38 Welcome to another episode of Eye Care insider :52 About Allisa Song 1:01 I want to hear your story about the history about the Nanodropper – how you came to this idea; what problem you were trying to solve; and how you got here? 2:02 What are the major advantages of your product? Why doesn't our standard bottle function properly like that? 5:06 Can this go on every eyedrop bottle? 6:49 Is there any sort of data that we can look at that shows how much volume of the prescription is saved? 7:51 Can you talk to me about how industry has taken this? What is your take on how they feel about your product? 12:15 How are you distributing your product to the consumers and to the masses? What are your channels to get the product out there? 15:36 What do you think the future holds for Nanodropper? Where do you see this going in the next 3 to 5 years? 17:04 Is there any information that you can provide to our listeners can go to and learn more about your story? 18:23 Congratulations again Allisa 19:03 You'll be graduating from medical school pretty soon? 19:15 Any final words to our listeners? 19:50 Outro 20:26   Allisa Song, is a Mayo Clinic Alix School of Medicine medical student and the CEO and co-founder of Nanodropper. Song is a serial entrepreneur and inventor with a background in Clean Tech, neuroscience, and harm reduction. In addition to her proven track record of successful fundraising, she has led her teams to dozens of business and design awards, including her most recent USPTO Collegiate Inventor medal awarded by the National Inventors Hall of Fame.  We'd love to hear from you! Send your comments/questions to Dr. Mali at eyecareinsider@healio.com. Follow us on Twitter @Healio_OSN. Song can be reached at support@nanodropper.com.   Disclosures: Mali reports he is founder and CEO of Mali Enterprises; retina medical director at Macular Degeneration Association; grant/research support from Alimera Sciences, Allergan/AbbVie, Chengdu Kanghong Biotechnology, Genentech, Notal Vision, Regeneron and Santen; consulting for Alimera Sciences, Allergan/AbbVie, Eyepoint Pharmaceuticals, Genentech, Kala Pharmaceuticals, Macular Degeneration Association, Notal Vision, Novartis, Regeneron and Sun Pharmaceuticals; speaker bureau for Alimera Sciences, Genentech, Kala Pharmaceuticals, Macular Degeneration Association, Notal Vision, Novartis and Sun Pharmaceuticals; and stock/shareholder with AbbVie and Regeneron. Song is the CEO and co-founder of Nanodropper and serves as an advisor for Bedo Solutions.

In this episode, Arthur Benjamin, MD, discusses dry eye treatment and trends, the challenges dry eye patients and the eye care professionals treating them and more. Intro :37 Welcome to another episode of Eye Care insider :51 About Arthur Benjamin, MD 1:02 I wonder if you could talk about your training and what you currently do now? 1:39 Could you talk about what you've seen throughout the years and what you've seen in the trends in dry eye and how it has expanded in the population? 2:56 What is your current algorithm for someone with dry eye? How do you manage that? 5:01 Once you do determine they have moderate dry eye where do you start with the patient or the treatment paradigm? 7:00 With the OptiLight treatment option … what do you tell patients? What should they be expecting? 9:54 I recently saw that there's been a campaign from OptiLight involving Mandy Moore. Could you talk about that campaign and discuss it a little bit further? 12:54 What do you think is the most important topic or issue or challenge that are facing dry eye patients today or eye care professionals treating patients with dry eye? 16:07 What a fascinating discussion 17:43 Any last words? 17:55 Outro 18:09 Arthur Benjamin, MD, is a clinical assistant professor at the Jules Stein/Doheny Eye Institute at UCLA's Geffen School of Medicine and is in private practice at Benjamin Eye Institute.   We'd love to hear from you! Send your comments/questions to Dr. Mali at eyecareinsider@healio.com. Follow us on Twitter @Healio_OSN. Dr. Benjamin can be contacted by going to BenjaminEye.com. Disclosures: Mali reports he is founder and CEO of Mali Enterprises; retina medical director at Macular Degeneration Association; grant/research support from Alimera Sciences, Allergan/AbbVie, Chengdu Kanghong Biotechnology, Genentech, Notal Vision, Regeneron and Santen; consulting for Alimera Sciences, Allergan/AbbVie, Eyepoint Pharmaceuticals, Genentech, Kala Pharmaceuticals, Macular Degeneration Association, Notal Vision, Novartis, Regeneron and Sun Pharmaceuticals; speaker bureau for Alimera Sciences, Genentech, Kala Pharmaceuticals, Macular Degeneration Association, Notal Vision, Novartis and Sun Pharmaceuticals; and stock/shareholder with AbbVie and Regeneron. Benjamin reports no relevant financial disclosures.

In this episode, Dhruvin Patel, MCOptom, discusses the short- and long-term effects of blue light on our eyes, how the pandemic has exacerbated these effects and how his company, Ocushield, is looking to help protect eyes from blue light. Intro :01 Patel's introduction and background :43 The science and necessity behind blue light blocking filters 5:35 Short-term effects of blue light on the eyes 7:15 Long-term effects of blue light on the eyes 8:24 Are eye care professionals doing enough to promote blue light protection? 12:11 Has the pandemic affected the demand/awareness of blue light related products? 14:25 Ocushield filters: what they are and how to get them 16:15 What makes Ocushield unique in the blue light/ophthalmic landscape? 19:03 How to contact Dr. Patel and Ocushield 20:31 Patel's final thoughts on our visual system and the importance of protecting it 21:11 Outro 22:01 Dhruvin Patel, MCOptom, is an optometrist and the founder of Ocushield. You can send your comments/questions directly to him at www.ocushield.com.  Follow him on Instagram, Facebook and Twitter @getocushield. We'd love to hear from you! Send your comments/questions to Dr. Mali at eyecareinsider@healio.com. Follow us on Twitter @Healio_OSN Disclosures: Mali reports he is founder and CEO of Mali Enterprises; retina medical director at Macular Degeneration Association; grant/research support from Alimera Sciences, Allergan/AbbVie, Chengdu Kanghong Biotechnology, Genentech, Notal Vision, Regeneron and Santen; consulting for Alimera Sciences, Allergan/AbbVie, Eyepoint Pharmaceuticals, Genentech, Kala Pharmaceuticals, Macular Degeneration Association, Notal Vision, Novartis, Regeneron and Sun Pharmaceuticals; speaker bureau for Alimera Sciences, Genentech, Kala Pharmaceuticals, Macular Degeneration Association, Notal Vision, Novartis and Sun Pharmaceuticals; and stock/shareholder with AbbVie and Regeneron. Patel is founder of Ocushield.

Briana Contreras, editor of Managed Healthcare Executive, spoke with Nancy Lurker, CEO and president of EyePoint Pharmaceuticals. Nancy shared a bit about EyePoint and how the organization's innovative therapies are addressing patient needs through eye care, and most importantly, she addressed C-Suite positions like the CEO role. Nancy shared advice for those seeking to reach the CEO level, especially toward women in healthcare and other roles, and what it takes to run a biopharma company. 

Our guest: Nancy Lurker, CEO at EyePoint PharmaceuticalsIn this episode, we discussed: Her background,  Overview of EyePoint Pharmaceuticals  Status of products in pipeline How to successfully run a publicly traded small biopharma company with happy patients and investors The difference from running a large vs. smaller pharma company Suggestions for women CEO's taking a similar approach or rising STEM majors on how best to navigate their career path This episode was recorded in January 2022. Our sponsors for this episode are BlocHealth, Curation Health, ChenMed & MediTelecare.BlocHealth is building the ecosystem of services and solutions to power the future of healthcare. For more information, please go to www.blochealth.com follow BlocHealth on social media - @blochealth"Curation Health's advanced clinical decision support platform seamlessly integrates into the electronic health record and leverages more than 750 proven clinical and quality rules. With this intelligent point-of-care platform, you can power a scalable risk adjustment process and amplify quality program performance." For more information, please go to www.curationhealthcare.com & follow Curation Health on social media - @curationhealth"ChenMed brings concierge-style medicine and better health outcomes to the neediest populations – moderate-to-low income seniors with complex chronic diseases. For more information, please go to www.chenmed.com & follow ChenMed on social media - @chenmed"MediTelecare provides behavioral telemedicine services to residents of skilled nursing and assisted living facilities, using state-of-the-art telehealth technology." For more information, please go to www.meditelecare.com & follow MediTelecare on social media – @meditelecareTo learn more about EyePoint Pharmaceuticals please use the links below:- Website - LinkedInAlso, be sure to follow Slice of Healthcare on our social channels:- Website - Facebook - LinkedIn - Twitter - YouTube - Newsletter

In this episode I share my top 5 predictions in ophthalmology for 2022, including my thoughts on the future of COVID-19 and ocular gene therapy. Welcome to another exciting episode of Eye Care insider :50 My top 5 predictions for 2022 1:16 Prediction #1 – on COVID-19 1:27 Prediction #2 – on wet AMD 2:43 Prediction #3 – on ocular gene therapy 4:05 Prediction #4 – on geographic atrophy 5:05 Prediction #5 – on ophthalmology media platforms 7:23 Thanks for listening 9:20 We'd love to hear from you! Send your comments/questions to Dr. Mali at eyecareinsider@healio.com. Follow us on Twitter @Healio_OSN. You can contact Mogan by going to the company's website, www.parkplacepayments.com or at Linkedin. Disclosures: Mali reports he is founder and CEO of Mali Enterprises; retina medical director at Macular Degeneration Association; grant/research support from Alimera Sciences, Allergan/AbbVie, Chengdu Kanghong Biotechnology, Genentech, Notal Vision, Regeneron and Santen; consulting for Alimera Sciences, Allergan/AbbVie, Eyepoint Pharmaceuticals, Genentech, Kala Pharmaceuticals, Macular Degeneration Association, Notal Vision, Novartis, Regeneron and Sun Pharmaceuticals; speaker bureau for Alimera Sciences, Genentech, Kala Pharmaceuticals, Macular Degeneration Association, Notal Vision, Novartis and Sun Pharmaceuticals; and stock/shareholder with AbbVie and Regeneron.

We discuss the DAVIO trial of EYP-1901 with Dr. Jay S. Duker, Chief Operating Officer of Eyepoint Pharmaceuticals.

We are kicking off 2022 with Nancy Lurker, a giant in the pharmaceutical industry. She has more than 30 years of experience in both start-ups and Fortune 500 companies. She's an accomplished businesswoman and leader with a track record of advancing new medical therapies and implementing very successful US and global drug launches. She also serves on many boards across public and private companies. Currently, she's the President and CEO of EyePoint Pharmaceuticals, an ocular drug delivery company for patients with serious eye disorders. In this episode, she shares some secrets to her success in the industry, and the leadership strategies that kept getting her promoted. Do you have any thoughts? Please email us at hello@rosenmaninstitute.org. We post new episodes every Monday. “The Health Technology Podcast” is produced by Herminio Neto, hosted by Christine Winoto, and engineered by Andrew John Rojek

 Is a technology that inhibits tyrosine kinase and shows activity against all isoforms of VEGF and placental growth factor the future of wet AMD therapy? Data from the DAVIO study, which were shared at the 2021 AAO Annual meeting late-breakers session, could be of interest. David Boyer, MD, discussed the drug design of EYP-1901 (EyePoint Pharmaceuticals) and summarized the findings of the phase 1 DAVIO study, which examined the drug's use in wet AMD patients. NRR also invited Firas Rahhal, MD, to review the safety and efficacy findings of the phase 3 NORSE-2 trial, which explored use of an ocular formation of bevacizumab (bevacizumab-vikg, Outlook Therapeutics) in patients with wet AMD. 

In this episode, Jennifer L. Mogan, MD, discusses her path into medicine, the importance of the credit card process and how it can be beneficial for eyecare practices. Welcome to another exciting episode of Eye Care insider :14 What led to the inception of the ‘Doctorpreneurship' series? :29 About Mogan 2:16 The interview 2:47 Give us an idea of your background, your training and why you went to medicine? 3:12 How in the world did you get involved with credit card processing? 4:12 Can you summarize the whole credit card processing process? Why should eye care professional or anybody in health care be aware of this structure and how will it affect their bottom line? 5:51 So, what are you finding in the market? Are physicians aware of this, are they not? And if they're not, how much is this potentially costing a practice? 11:37 How can they implement these strategies in practice or what services can your company offer eyecare professionals in helping to solve this problem? 12:46 Have you seen an uptake in business recently because of practices trying to minimize their expenses by lowering these rates? 13:57 How to find Mogan 14:35 What do you love about being a Doctorpreneur and do you have any advice or pearls for the audience? 15:02 Thank you, Dr. Mogan for all your great advice and tips 16:07 Jennifer L. Mogan, MD, is an anesthesiology specialist with Rochester Regional Health and a senior account specialist for Park Place Payments.   We'd love to hear from you! Send your comments/questions to Dr. Mali at eyecareinsider@healio.com. Follow us on Twitter @Healio_OSN. You can contact Mogan by going to the company's website, www.parkplacepayments.com or at Linkedin. Disclosures: Mali reports he is founder and CEO of Mali Enterprises; retina medical director at Macular Degeneration Association; grant/research support from Alimera Sciences, Allergan/AbbVie, Chengdu Kanghong Biotechnology, Genentech, Notal Vision, Regeneron and Santen; consulting for Alimera Sciences, Allergan/AbbVie, Eyepoint Pharmaceuticals, Genentech, Kala Pharmaceuticals, Macular Degeneration Association, Notal Vision, Novartis, Regeneron and Sun Pharmaceuticals; speaker bureau for Alimera Sciences, Genentech, Kala Pharmaceuticals, Macular Degeneration Association, Notal Vision, Novartis and Sun Pharmaceuticals; and stock/shareholder with AbbVie and Regeneron. Mogan is a senior account specialist for Park Place Payments.

In this episode, Sue Washer, BS, MBA, discusses gene therapy in ophthalmology, ATGC's clinical trial progress, as well as current and future challenges faced by both the cell therapy industry and ophthalmology. Welcome to another exciting episode of Eye Care insider :13 About Washer 1:51 Can you discuss what is gene therapy? How does it work on a basic level? 4:53 How do companies like AGTC make gene therapy work for diseases that may not affect as many people but still make it financially successful for investors? 7:11 Could you talk about where you are in the X-Linked Retinitis Pigmentosa candidate trials? 11:08 Is there an estimated timeline that you have for initial data read out? 14:56 You have another candidate for achromatopsia … I was reading you had some new data released. Could you go into more details about that? 16:23 What do you think is the most important topic or challenge you see facing the gene therapy industry and ophthalmology today and in the future? 20:56 Thank you so much for your insight into this fascinating topic 23:22 How to find out more about AGTC 23:31 Thank you for listening 24:15 Sue Washer, BS, MBA is the president and chief executive officer of AGTC. We'd love to hear from you! Send your comments/questions to Dr. Mali at eyecareinsider@healio.com. Follow us on Twitter @Healio_OSN. You can contact AGTC through the company's website at www.atgc.com. Disclosures: Mali reports he is founder and CEO of Mali Enterprises; retina medical director at Macular Degeneration Association; grant/research support from Alimera Sciences, Allergan/AbbVie, Chengdu Kanghong Biotechnology, Genentech, Notal Vision, Regeneron and Santen; consulting for Alimera Sciences, Allergan/AbbVie, Eyepoint Pharmaceuticals, Genentech, Kala Pharmaceuticals, Macular Degeneration Association, Notal Vision, Novartis, Regeneron and Sun Pharmaceuticals; speaker bureau for Alimera Sciences, Genentech, Kala Pharmaceuticals, Macular Degeneration Association, Notal Vision, Novartis and Sun Pharmaceuticals; and stock/shareholder with AbbVie and Regeneron. Washer is the president and CEO of AGTC.

In this episode, the third of a three-part series, John B. Pinto discusses some of the future megatrends expected for ophthalmic practices, challenge practices may face in the future, and more. Intro :13 What you think the megatrends are going to be over the next decade or so in the ophthalmic practices :50 What do you think is the most important topic or issue or challenge facing ophthalmic practices now and in the future? 4:46 If our listeners wanted to learn more, what's the best way to contact you? 10:02 I really appreciate you and all your great advice 10:47 Any final words? 11:00 Thank you so much John, I appreciate it 11:16 John B. Pinto is president of J. Pinto & Associates, Inc. He is also a practice consultant and the author of several books on ophthalmic practice management, including John Pinto's Little Green Book of Ophthalmology, UP (with Corinne Wohl), Simple, and Ophthalmic Leadership. UP: Taking Ophthalmic Administrators and Their Management Teams to the Next Level of Skill, Performance and Career Satisfaction, Second Edition is a powerful, practical workbook by Corinne Wohl, MHSA, COE and John B. Pinto designed to take ophthalmic administrators and practice managers to the next level of their careers, offering practical tips, concrete advice, and a step-by-step guide for any hurdle they face. Available now for purchase at slackbooks.com/management. Receive 20% off with promo code PINTO20. We'd love to hear from you! Send your comments/questions to Dr. Mali at eyecareinsider@healio.com. Follow us on Twitter @Healio_OSN. Disclosures: The Wyanoke Group is the parent company of Healio and SLACK Books. Mali reports he is founder and CEO of Mali Enterprises; retina medical director at Macular Degeneration Association; grant/research support from Alimera Sciences, Allergan/AbbVie, Chengdu Kanghong Biotechnology, Genentech, Notal Vision, Regeneron and Santen; consulting for Alimera Sciences, Allergan/AbbVie, Eyepoint Pharmaceuticals, Genentech, Kala Pharmaceuticals, Macular Degeneration Association, Notal Vision, Novartis, Regeneron and Sun Pharmaceuticals; speaker bureau for Alimera Sciences, Genentech, Kala Pharmaceuticals, Macular Degeneration Association, Notal Vision, Novartis and Sun Pharmaceuticals; and stock/shareholder with AbbVie and Regeneron.

Nancy Lurker: President & Chief Executive Officer Our President, CEO, and a director since September 2016, Ms Lurker has broad-ranging experience in the pharmaceutical industry and a track record of maximizing the potential of new therapies and successfully implementing innovative US and global drug launches. Said Saim, PhD: Chief Technology Officer Dr Saim has more than 25 years of product development experience. Dr Saim has published 22 papers in engineering and science journals, holds 18 patents, and earned a PhD in chemical engineering from the University of Kansas.

In this second episode of a three-part series, John B. Pinto discusses the job market for early-career professionals and new graduates, his perspective on what ophthalmologists have learned from the pandemic and the role telemedicine will play in the future of ophthalmology. Intro :14 What is the current negotiation position in the market for early-career and new graduate ophthalmic practice physicians? :41 I'd love to hear your perspective on what we have learned about our practices after a year of this pandemic 3:35 How is the telemedicine trend going now? Is telemedicine here to stay? 11:09 Tell us about your upcoming book and your insight into it? 12:59 Stay tuned for the next episode of this special three-part miniseries 17:38 John B. Pinto is president of J. Pinto & Associates, Inc. He is also a practice consultant and the author of several books on ophthalmic practice management, including John Pinto's Little Green Book of Ophthalmology, UP (with Corinne Wohl), Simple, and Ophthalmic Leadership. UP: Taking Ophthalmic Administrators and Their Management Teams to the Next Level of Skill, Performance and Career Satisfaction, Second Edition is a powerful, practical workbook by Corinne Wohl, MHSA, COE and John B. Pinto designed to take ophthalmic administrators and practice managers to the next level of their careers, offering practical tips, concrete advice, and a step-by-step guide for any hurdle they face. Available now for purchase at slackbooks.com/management. Receive 20% off with promo code PINTO20. We'd love to hear from you! Send your comments/questions to Dr. Mali at eyecareinsider@healio.com. Follow us on Twitter @Healio_OSN. Disclosures: The Wyanoke Group is the parent company of Healio and SLACK Books. Mali reports he is founder and CEO of Mali Enterprises; retina medical director at Macular Degeneration Association; grant/research support from Alimera Sciences, Allergan/AbbVie, Chengdu Kanghong Biotechnology, Genentech, Notal Vision, Regeneron and Santen; consulting for Alimera Sciences, Allergan/AbbVie, Eyepoint Pharmaceuticals, Genentech, Kala Pharmaceuticals, Macular Degeneration Association, Notal Vision, Novartis, Regeneron and Sun Pharmaceuticals; speaker bureau for Alimera Sciences, Genentech, Kala Pharmaceuticals, Macular Degeneration Association, Notal Vision, Novartis and Sun Pharmaceuticals; and stock/shareholder with AbbVie and Regeneron.

If you are passionate about the markets and want to a be a part of the Zingernation community and you can write, code, edit or are a genius at marketing email us at powerhour@benzinga.comOn Power Hour Today:Swing trade $RIDE?Buy $DKNG?What is happening with Roblox?Special Guest:Nancy Lurker, CEO EyePoint Pharmaceuticals, Inc. $EYPT 28:00Get 20% off Benzinga PRO➡️https://benzinga.grsm.io/youtube20Hosts:Jason RaznickTwitter: https://twitter.com/jasonraznickHot Stocks Luke JacobiTwitter: https://twitter.com/lukejacobiSupport this podcast at — https://redcircle.com/zingernation-power-hour/exclusive-contentAdvertising Inquiries: https://redcircle.com/brandsPrivacy & Opt-Out: https://redcircle.com/privacy

In this episode, the first of a three-part series, John B. Pinto discusses how he got started in ophthalmic practice management, shares an historical perspective on the field, plus his advice for physicians. Intro :16 About John Pinto :54 On Pinto's background, why he went into the ophthalmic practice management industry 1:39 Can you give listeners a historical perspective of how has ophthalmic practice management changed or evolved over the last 40 years? 7:13 What is the current state of ophthalmic practice management in America today? 13:11 Could you give a key pearl for how to handle practice management as an early- or mid-career physician as well as a late-career/ retirement-age physician? 16:02 In your experience, what would you say would be the average age of full retirement in ophthalmology? 23:56 Stay tuned for the next episode of this special three-part miniseries 27:19 John B. Pinto is president of J. Pinto & Associates, Inc. He is also a practice consultant and the author of several books on ophthalmic practice management, including John Pinto's Little Green Book of Ophthalmology, UP (with Corinne Wohl), Simple, and Ophthalmic Leadership. UP: Taking Ophthalmic Administrators and Their Management Teams to the Next Level of Skill, Performance and Career Satisfaction, Second Edition is a powerful, practical workbook by Corinne Wohl, MHSA, COE and John B. Pinto designed to take ophthalmic administrators and practice managers to the next level of their careers, offering practical tips, concrete advice, and a step-by-step guide for any hurdle they face. Available now for purchase at slackbooks.com/management. Receive 20% off with promo code PINTO20. We'd love to hear from you! Send your comments/questions to Dr. Mali at eyecareinsider@healio.com. Follow us on Twitter @Healio_OSN. Disclosures: The Wyanoke Group is the parent company of Healio and SLACK Books. Mali reports he is founder and CEO of Mali Enterprises; retina medical director at Macular Degeneration Association; grant/research support from Alimera Sciences, Allergan/AbbVie, Chengdu Kanghong Biotechnology, Genentech, Notal Vision, Regeneron and Santen; consulting for Alimera Sciences, Allergan/AbbVie, Eyepoint Pharmaceuticals, Genentech, Kala Pharmaceuticals, Macular Degeneration Association, Notal Vision, Novartis, Regeneron and Sun Pharmaceuticals; speaker bureau for Alimera Sciences, Genentech, Kala Pharmaceuticals, Macular Degeneration Association, Notal Vision, Novartis and Sun Pharmaceuticals; and stock/shareholder with AbbVie and Regeneron.

Join us in a discussion with Jay S. Duker, MD Chief Strategic Scientific Officer of EyePoint Pharmaceuticals. Director of New England Eye Center, Professor and Chair of Ophthalmology at Tufts University School of Medicine with our moderator Dr. Carmen Puliafito.